Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT02958865 |
Date of registration:
|
04/11/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
|
Scientific title:
|
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS |
Date of first enrolment:
|
February 3, 2017 |
Target sample size:
|
319 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02958865 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
Austria
|
Bulgaria
|
Canada
|
Czechia
|
Denmark
|
Georgia
|
Germany
|
Hungary
|
Israel
|
Italy
|
Korea, Republic of
|
Netherlands
|
Poland
|
Romania
|
Russian Federation
|
Serbia
|
Slovakia
|
Spain
|
Turkey
|
Ukraine
|
United States
| | | |
Contacts
|
Name:
|
Pfizer CT.gov Call Center |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Pfizer |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|